Hematopoietic Stem Cells Transplantation Can Normalize Thyroid Function in a Cystinosis Mouse Model.

Permalink
https://escholarship.org/uc/item/4nq14291

Journal
Endocrinology, 157(4)

ISSN
0013-7227

Authors
Gaide Chevronnay, HP
Janssens, V
Van Der Smissen, P
et al.

Publication Date
2016-04-01

DOI
10.1210/en.2015-1762

Peer reviewed
Hematopoietic Stem Cells Transplantation Can Normalize Thyroid Function in a Cystinosis Mouse Model

H. P. Gaide Chevronnay,* V. Janssens,* P. Van Der Smissen, C. J. Rocca, X. H. Liao, S. Refetoff, C. E. Pierreux, S. Cherqui,† and P. J. Courtoy†

Cell Biology Unit (H.P.G.C., V.J., P.V.D.S., C.E.P., P.J.C.), de Duve Institute and Université Catholique de Louvain, 1200 Brussels, Belgium; Department of Pediatrics (C.J.R., S.C.), Division of Genetics, University of California, San Diego, San Diego, California 92161; and Departments of Medicine (X.H.L., S.R.) and Pediatrics and Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637

Hypothyroidism is the most frequent and earliest endocrine complication in cystinosis, a multisystemic lysosomal storage disease caused by defective transmembrane cystine transporter, cystinosin (CTNS gene). We recently demonstrated in Ctns−/− mice that altered thyroglobulin biosynthesis associated with endoplasmic reticulum stress, combined with defective lysosomal processing, caused hypothyroidism. In Ctns−/− kidney, hematopoietic stem cell (HSC) transplantation provides long-term functional and structural protection. Tissue repair involves transfer of cystinosin-bearing lysosomes from HSCs differentiated as F4/80 macrophages into deficient kidney tubular cells, via tunneling nanotubes that cross basement laminae. Here we evaluated the benefit of HSC transplantation for cystinotic thyroid and investigated the underlying mechanisms. HSC engraftment in Ctns−/− thyroid drastically decreased cystine accumulation, normalized the TSH level, and corrected the structure of a large fraction of thyrocytes. In the thyroid microenvironment, HSCs differentiated into a distinct, mixed macrophage/dendritic cell lineage expressing CD45 and major histocompatibility complex II but low CD11b and F4/80. Grafted HSCs closely apposed to follicles and produced tunneling nanotube-like extensions that crossed follicular basement laminae. HSCs themselves further squeezed into follicles, allowing extensive contact with thyrocytes, but did not transdifferentiate into Nkx2.1-expressing cells. Our observations revealed significant differences of basement lamina porosity between the thyroid and kidney and/or intrinsic macrophage invasive properties once in the thyroid microenvironment. The contrast between extensive thyrocyte protection and low HSC abundance at steady state suggests multiple sequential encounters and/or remnant impact. This is the first report demonstrating the potential of HSC transplantation to correct thyroid disease and supports a major multisystemic benefit of stem cell therapy for cystinosis. (Endocrinology 157: 1363–1371, 2016)

Infantile cystinosis is an inherited multisystemic lysosomal storage disease, in which cystine, an obligatory degradation product of disulphide bearing proteins, fails to exit lysosome due to genetic inactivation of its transmembrane transporter, cystinosin (CTNS gene) (1). Additional roles of cystinosin, such as mammalian target of rapamycin complex 1 regulation, have recently been demonstrated (2). Cystinosis typically manifests itself before 1 year of age as renal Fanconi syndrome, ie, generalized proximal tubular cell (PTC) dysfunction, and inevitably evolves to renal insufficiency. Primary (TSH compensated) hypothyroidism is the earliest and almost
obligatory endocrine dysfunction in cystinotic children (3, 4).

Cystinosin-deficient mice in a strict congenic C57/BL6 background (Ctns<sup>−/−</sup> mice) mimic human cystinosis (5) and proved informative to unravel early pathogenic and adaptive mechanisms in kidneys and thyroid (6–9). In Ctns<sup>−/−</sup> kidneys, impaired apical receptor-mediated endocytosis, endolysosomal trafficking, and lysosomal proteolysis are associated to PTC dedifferentiation (6, 7). In Ctns<sup>−/−</sup> thyroid, altered thyroglobulin biosynthesis with endoplasmic reticulum (ER) stress, combined with defective lysosomal processing of iodothyroglobulin, lead to impaired thyroid hormone production, resulting in subclinical hypothyroidism (increased TSH), thyrocyte hyperplasia/hypertrophy, and accelerated cell turnover (8).

Lysosomal cystine accumulation can be corrected by substrate depletion therapy with cysteamine, the only current approved drug. Cysteamine reacts with lysosomal cystine to form mixed cysteamine/cysteine disulphide that exits lysosome by the lysine transporter system (10). However, cysteamine therapy is very demanding and even early implementation in compliant patients fails to prevent renal insufficiency and thyroid dysfunction (11, 12). Alternative therapies are thus needed. Recent reports demonstrated a major benefit of hematopoietic stem cell (HSC) transplantation to prevent kidney disease progression and corneal defects in Ctns<sup>−/−</sup> mice, as evidenced by decreased cystine level and long-term functional protection (13–16). Engrafted HSC-derived cells mostly expressed the common macrophage markers F4/80 and major histocompatibility complex II (MHCII) and did not fuse with kidney epithelial cells nor keratocytes (15–17). In coculture experiments, bone marrow–derived macrophages generated tunneling nanotubes (TNTs) whereby cystinosin bearing-lysosomes were transported into Ctns-deficient fibroblasts (17). Conversely, lysosomes of Ctns-deficient fibroblasts used the same physical connection toward wild-type (WT) macrophages, to fuse with the competent lysosomal pool (17). In vivo, HSCs grafted in Ctns<sup>−/−</sup> kidney also generated TNT-like structures that crossed basement laminae and connected with epithelial cells, which acquired cystinosin (17). These data provided the first demonstration of cross-correction of a genetic lysosomal storage disease. The same mechanism was recently documented in the cornea (16). We here document the remarkable benefits of HSC transplantation in Ctns<sup>−/−</sup> thyroid and define structural protective mechanisms.

**Materials and Methods**

**Mice**

WT Ctns<sup>++/+</sup>, enhanced green fluorescent protein (eGFP)-transgenic mice (C57BL/6-Tg[ACTB-EGFP]1Osb/J) were from Jackson Laboratory. Cross-breeding of DsRed-transgenic mice (B6.Cg-Tg[CAG-DsRed*MST]1Nagy/J; Jackson Laboratory) with C57BL/6 Ctns<sup>−/−</sup> mice generated by Dr C. Antignac (5) produced transgenic DsRed Ctns<sup>−/−</sup> mice, ubiquitously expressing the DsRed fluorescent protein (15). Protocols were approved by University of California, San Diego, Animal Care and Use Committee. Mice were fed ad libitum with pellets containing 3 mg/kg iodine (Harlan Laboratories).

**HSCs isolation and transplantation**

Bone marrow cells were collected from WT eGFP-transgenic mice. Sca1<sup>+</sup> HSCs selected by immunomagnetic separation (Miltenyi Biotec) were transplanted iv into 2-month-old DsRed Ctns<sup>−/−</sup> mice, irradiated (8 Gy) on the previous day (17). Because histological changes appeared in Ctns<sup>−/−</sup> thyroid around 6 months and became prominent 2–3 months thereafter (8), Ctns<sup>−/−</sup> mice transplanted with WT-eGFP HSCs (grafted Ctns<sup>−/−</sup> mice) were analyzed at 8 months of age/6 months after transplantation and compared with age-matched WT and Ctns<sup>−/−</sup> mice. Older mice were occasionally examined. We studied 10 WT (four males; six females), 15 Ctns<sup>−/−</sup> mice (four males; 11 females), and 16 grafted Ctns<sup>−/−</sup> mice (six males; 10 females).

**Biochemical assays**

Thyroid cystine and plasma TSH, T<sub>3</sub>, and T<sub>4</sub> were measured as described (14, 18).

**Microscopy**

Perfusion-fixed thyroids were dissected and postfixed overnight with 4% neutral-buffered formaldehyde (7). Thyroid lobes were either equilibrated in 20% sucrose, embedded in Tissue-Tek/optimum cutting temperature, and snap frozen in isopentane or processed for paraffin embedding. For histological analysis, 4-μm-thick paraffin sections were stained with hematoxylin/eosin. Immunofluorescence was performed as described, using antibodies listed in Table 1 (7). HSCs were identified by immunofluorescence instead of intrinsic GFP fluorescence because of its inactivation during tissue paraffin processing and rapid photobleaching in frozen sections and to amplify detection sensitivity in cytoplasmic extensions. For detection of inflammatory cell markers, blocking solution with 10% normal goat serum and 2% milk was used. Alexa-fluor antibodies were selected, at the exclusion of red fluorophores for frozen sections, to avoid confusion with DsRed endogenous emission. Antigen retrieval in citrate buffer (pH 6.0) was performed for E-cadherin, lysosome-associated membrane protein-1 (LAMP-1), the tetra-amino acid sequence for ER retention (KDEL), zona occludens-1 (ZO-1), F4/80, and NKx2.1. Sections were imaged with a spinning disk confocal microscope using EC Plan-NeoFluar ×40/1.3 or Plan Apochromat ×100/1.4 Oil DIC objectives (cell observer spinning disk; Zeiss), and pseudocolors were assigned afterward using AxioVision Rel. 4.8 software. Electron microscopy was performed as described (8).

**Statistical analysis**

Statistical significance was tested using the Mann-Whitney test. Differences were considered significant for P < .05.
Results

HSC transplantation into Ctns−/− mice normalizes thyroid function and protects follicular structures

We recently reported that Ctns−/− mice develop between 6 and 9 months subclinical hypothyroidism with multifocal thyrocyte hyperplasia/hypertrophy and colloid exhaustion as cystinotic patients. Increased Ctns−/− thyrocyte apoptosis and proliferative repair revealed accelerated cell turnover (8). Clinical benefit of early WT-eGFP-HSC transplantation was first assessed by measuring thyroid cystine and plasma hormone levels. Grafting of HSC transplantation was first assessed by measuring thyroid function and protects follicular structures (Figure 1A), half of them showing normal plasma T4 and TSH levels (Figure 1B). By conventional histopathology, grafted Ctns−/− thyroids showed striking overall improvement over nongrafted controls, as evidenced by predominantly normal thyrocyte height and homogeneous colloid filling (Figure 1Cc). Thyrocyte proliferation (Ki-67 immunolabeling), was decreased by approximately 60% upon transplantation, in agreement with hyperplasia correction (Figure 1D; Supplemental Figure 1). This analysis also revealed the proliferation of WT-eGFP-HSCs, indicating local graft expansion in cystinotic thyroid (Figure 1Dc and insert). Altogether these data demonstrated a remarkable benefit of early engraftment of WT-eGFP-HSCs to correct thyroid disease progression in Ctns−/− mice.

WT-eGFP-HSCs transplantation improves biosynthetic and lysosomal overload in Ctns−/− thyroid

We thus looked for protection by HSC transplantation against subcellular alterations induced by cystinosis (8). Upon grafting, we found a major decrease of ER expansion in most Ctns−/− thyrocytes, as monitored by KDEL immunolabeling, suggesting relief of ER stress (Figure 2A). Endolysosomal status of grafted Ctns−/− thyroids, monitored by LAMP-1 immunolabeling (Figure 2B) and electron microscopy (Supplemental Figure 2), was very heterogeneous: regions apparently normal upon grafting, elsewhere very much altered, but no cystine crystal could be detected, in contrast to nongrafted Ctns−/− thyroids (Supplemental Figure 2). Of note, neither cystinosis (data not shown) nor HSC engraftment and follicular infiltration (see below) disrupted thyrocyte tight junction integrity, thus epithelial barrier (Supplemental Figure 2).

Thyroid-grafted WT-eGFP-HSCs emit tunneling nanotube-like expansions able to cross follicle basement lamina

We next addressed the mechanism(s) of HSC-mediated tissue protection in a bifluorescent mouse model (17), which allows to discriminate the fate of green WT-eGFP-HSCs transplanted into DsRed mice (here identifying Ctns−/− thyrocytes). No grafted WT-eGFP-HSCs simultaneously expressed DsRed (Figure 3A, no yellow signal), thereby excluding cell fusion as protective mechanism. WT-eGFP-HSCs with dendritic-like shape frequently apposed onto follicular basement laminae (Figure 3, Aa, Ab, and Ba), which they further crossed by long cytoplasmic extensions, either very thin (stricto sensu tunneling nanotubes) or much thicker with budding tips (Figure 3Ba–c). Furthermore, several WT-eGFP-HSCs became completely inserted inside follicles, intertwined with thyrocytes (arrowheads in Figure 3Aa, Ab, and Ba and Supplemental Figure 3). Inserted WT-eGFP-HSCs thus enjoyed extensive close contact with adjacent Ctns−/− thyrocytes, which was never found in Ctns−/− kidney PTCs (see below). Lateral extensions of individually inserted HSCs could further contact several thyrocytes (Supplemental Figure 3). Follicular basement lamina porosity to invading cells could be due to tissue-specific difference between thyroid

Table 1. Antibody Table

<table>
<thead>
<tr>
<th>Peptide/Protein Target</th>
<th>Antigen Sequence</th>
<th>Name of Antibody</th>
<th>Manufacturer, Catalog #</th>
<th>Species Raised in: Monoclonal or Polyclonal</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-cadherin</td>
<td></td>
<td>Anti-E-cadherin</td>
<td>DB Bioscience, 610 182</td>
<td>Mouse monoclonal (clone 36)</td>
<td>0.25 µg/ml</td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td>Anti-Ki-67</td>
<td>DB Pharmingen, 556 003</td>
<td>Mouse monoclonal (clone B56)</td>
<td>2 µg/ml</td>
</tr>
<tr>
<td>Nkx2-1</td>
<td></td>
<td>Anti-Thyroid Transcription Factor-1</td>
<td>Dako, M3575</td>
<td>Mouse monoclonal (clone G7G3/1)</td>
<td>1/500</td>
</tr>
<tr>
<td>GFP</td>
<td></td>
<td>Anti-GFP</td>
<td>Cell signaling, 2956</td>
<td>Rabbit monoclonal</td>
<td>1/200</td>
</tr>
<tr>
<td>GFP</td>
<td>aa246</td>
<td>Anti-GFP</td>
<td>Abcam, ab6673</td>
<td>Goat polyclonal</td>
<td>1/250</td>
</tr>
<tr>
<td>Laminin</td>
<td></td>
<td>Anti-laminin</td>
<td>Sigma, L9393</td>
<td>Rabbit monoclonal</td>
<td>2.5 µg/ml</td>
</tr>
<tr>
<td>F4/80</td>
<td></td>
<td>Anti-F4/80</td>
<td>Abcam, ab6640</td>
<td>Rabbit monoclonal</td>
<td>5 µg/ml</td>
</tr>
<tr>
<td>F4/80</td>
<td></td>
<td>Anti-F4/80</td>
<td>eBioscience, 14-4801</td>
<td>Rabbit monoclonal</td>
<td>3.4 µg/ml</td>
</tr>
<tr>
<td>MHCIi</td>
<td></td>
<td>Anti-MHC class II (I-A/I-E)</td>
<td>Milipore, MA8933</td>
<td>Rabbit monoclonal</td>
<td>5 µg/ml</td>
</tr>
<tr>
<td>CD11b</td>
<td></td>
<td>Anti-CD11b</td>
<td>Biologic, 101 202</td>
<td>Rabbit monoclonal</td>
<td>10 µg/ml</td>
</tr>
<tr>
<td>CD11c</td>
<td></td>
<td>Anti-CD11c</td>
<td>Abcam, ab11029</td>
<td>Rabbit monoclonal</td>
<td>5 µg/ml</td>
</tr>
<tr>
<td>CD45</td>
<td></td>
<td>Anti-CD45</td>
<td>Biologic, 103 102</td>
<td>Rabbit monoclonal</td>
<td>10 µg/ml</td>
</tr>
<tr>
<td>Ly6C</td>
<td></td>
<td>Anti-Ly6C</td>
<td>Thermo Scientific, MA-81 899</td>
<td>Rabbit monoclonal (ER-M20)</td>
<td>10 µg/ml</td>
</tr>
<tr>
<td>KDEL</td>
<td></td>
<td>Anti-KDEL</td>
<td>Abcam, ab50601</td>
<td>Rabbit monoclonal (MAC 256)</td>
<td>1/300</td>
</tr>
<tr>
<td>LAMP-1</td>
<td></td>
<td>Anti-LAMP-1 1D4B</td>
<td>Hybridea Bank, #1D4B</td>
<td>Rabbit monoclonal (clone 1D4B)</td>
<td>1/75</td>
</tr>
</tbody>
</table>
and kidneys, combined with cystinosis-related alterations (Supplemental Figure 4). Indeed, follicular basement lamina in nongrafted Ctns<sup>−/−</sup> mice lost normal circularity (indicating lesser tensile strength) and disclosed large discontinuities, which were not seen in grafted congeners.

**Distinct phenotype of thyroid-engrafted WT-eGFP-HSCs**

Macrophages form a plastic population (20) yet poorly characterized in thyroid disease. In Ctns<sup>−/−</sup> liver, brain, and kidneys, HSC-derived...
cells mainly differentiate into F4/80\textsuperscript{high} macrophages (13–15, 17). We thus looked at macrophage abundance and differentiation markers in WT, Ctns\textsuperscript{−/−}, and grafted Ctns\textsuperscript{−/−} thyroid. In the WT thyroid, F4/80\textsuperscript{+} macrophages were extremely rare but became massively recruited in Ctns\textsuperscript{−/−} mice between 6 and 9 months of age, concomitant with histoarchitectural alterations (Supplemental Figure 6). Most such endogenous macrophages further inserted into Ctns\textsuperscript{−/−} follicles, like WT-eGFP-HSCs described above (Figure 4Ab and Supplemental Figure 6F). In the grafted Ctns\textsuperscript{−/−} thyroid, much fewer endogenous F4/80\textsuperscript{+} macrophages were observed, probably due to considerable correction of tissue injury (for full thyroid section, see Supplemental Figure 7). We next attempted to better define the status of engrafted WT-eGFP-HSC-derived cells. CD45 confirmed hematopoietic cell lineage origin (Figure 4B), but F4/80 was rarely detected, arguing against conventional macrophages (Figure 4, Ac and B). This differed from other cystinotic tissues such as the kidneys, indicating a unique role of the thyroid microenvironment (Supplemental Figure 8). Most engrafted WT-eGFP-HSC-derived cells expressed MHCII, consistent with healing differentiation (16). The signal for the CD11b macrophage marker was weak, and neither Ly6c nor CD11c was detected (Figure 4B). These data indicated that HSC-derived cells grafted into Ctns\textsuperscript{−/−} thyroid apparently replaced typical endogenous F4/80\textsuperscript{+} macrophages recruited in nongrafted congeners and acquired in this particular tissue microenvironment a distinct combination of macrophage/dendritic differentiation markers. Of note, the steady-state abundance of grafted, particularly follicle-apposed and inserted HSCs, was very low as compared with the high prevalence of apparently protected thyrocytes (Supplemental Figure 7).

**Discussion**

We here report that HSC transplantation can protect thyroid structure and normalize function in a mouse model of cystinosis (Ctns\textsuperscript{−/−}), a lysosomal storage disease due to defective membrane transporter. Thyroid-engrafted HSCs generate

---

**Figure 2.** Improvement by HSC transplantation of biosynthetic and lysosomal overload in Ctns\textsuperscript{−/−} thyroid. Eight-month-old/6-month posttransplant Ctns\textsuperscript{−/−} mice were compared with age-matched WT and Ctns\textsuperscript{−/−} mice. Samples were analyzed by double immunofluorescence for E-cadherin (red, thyrocyte structure) and either (green) KDEL, as generic marker of endoplasmic reticulum residents (A), or LAMP-1, as lysosomal membrane marker (B). A, ER expansion. In WT follicles (a), thyrocytes are flat or cuboidal, and the ER mostly occupies the basal cytoplasm. In nongrafted Ctns\textsuperscript{−/−} mice (b), thyrocytes are columnar (hypertrophic, reaching ~20 μm in height), and KDEL labeling fills the lumen of dilated ER (arrows), which is spread over the entire cytoplasm. Upon grafting (c), Ctns\textsuperscript{−/−} thyrocyte height is generally decreased and the ER is overall reduced as compared with panel b. However, KDEL antibodies occasionally delineate larger structures devoid of luminal signal (arrow). B, Lysosome abnormalities. In WT thyrocytes (a), LAMP-1-labeled structures are dotty and sparse along the cytoplasm. In nongrafted Ctns\textsuperscript{−/−} thyrocytes (b), many lysosomes are dilated and concentrated at the apical pole (arrows and enlarged in insert). LAMP-1 also labels cell remnants in the follicular lumen. Panels c and d show two distinct patterns of grafted Ctns\textsuperscript{−/−} thyrocytes. In panel c, the aspect is comparable with WT (ie, preserved). In panel d, enlarged lysosomes are obvious, even frequently larger than in panel b. For electron microscopy, see Supplemental Figure 2 (crystals were detected only in nongrafted Ctns\textsuperscript{−/−} thyrocytes).
MHCIı-positive macrophage/dendritic lineage instead of homogenous F4/80 labeling found in engrafted kidneys and eyes, pointing to a unique role of thyroid microenvironment in macrophage differentiation.

Stem cell transplantation is now a therapeutic option for a broad range of congenital or acquired disorders (21) but has never been validated for thyroid disorders. On the contrary, case reports suggested that HSCs may trigger autoimmune thyroiditis and favor thyroid cancer, although indirect effects of myeloablation are unclear (22, 23). However, in a mouse model of Hashimoto’s disease, mesenchymal stem cells efficiently reduced inflammation and improved clinical outcome (24, 25). We here demonstrate that bone marrow-derived HSCs can partially protect Ctns<sup>−/−</sup> thyroid structure and normalize function. These data further support a major multisystemic benefit of stem cells therapy for cystinosis, in particular thyroid protection, and suggest it may represent a generic treatment for membrane protein defects. A clinical trial is currently being developed for human cystinosis based on autologous transplantation of ex vivo lentivirus-transduced HSCs combined with myeloablation by chemotherapy.

In Ctns<sup>−/−</sup> kidneys and corneas, tissue repair by engrafted HSCs involves TNT formation and transfer into deficient cells of cystinosin-bearing lysosomes as correcting factor, ie, cross-correction (16, 17). HSC recruitment thus cannot be primarily related to the altered thyroid state but to the general disease (13, 16). However, the thyroid seems so far unique because HSCs not only emit TNT-like structures able to cross (damaged?) follicular base-
lymphocytes and thyrocytes, rendering possible transfer of material, have been evidenced in Hashimoto’s thyroiditis (28). Altogether these observations suggest that the thyroid is more prone to full HSC infiltration across basement lamina as compared with the kidney in which HSC bodies are restricted around tubules (13, 14, 17) and that HSCs, once fully infiltrated within the epithelial monolayer, enjoy close vicinity with cystinotic thyrocytes, which should favor efficient correction as testified by the normalization of thyroid function in most Ctns−/− mice.

A striking discrepancy was further noted between the low abundance of thyrocyte-contacting HSCs at steady state and the remarkable extent of tissue protection. This discrepancy favors the view of multiple cross-corrective interactions, ie, the ability of individual dendritic-shaped HSCs to simultaneously interact with several adjacent disease cells combined with HSC mobility, allowing iterative exchange of correcting organelles at each new location over time.

Overall histological and functional protection was, however, not matched by general subcellular preservation. Tissue heterogeneity, between and within follicles, is not really surprising if protection depends on local physical connections. A deleterious effect of irradiation also can not be excluded, although not supported by previous investigations (13). Considering the thyroid functional reserve whereby independent follicles contribute in parallel to total thyroid hormone production, incomplete structural protection may still support adequate functional correction.

In the Ctns−/− thyroid, engrafted WT HSCs alleviate the afflux of endogenous cystinotic F4/80+ macrophages, as also observed in the kidney (14), probably due to the correction of tissue injury. Most WT HSC-derived cells in the cystinotic thyroid expressed CD45 and MHCII as opposed to conventional F4/80+ macrophages, suggesting a distinct differentiation in Ctns−/− thyroid vs kidneys and corneas, likely due to the cystinotic thyroid microenviroments.

Figure 4. Grafted WT-HSCs replace endogenous Ctns−/− macrophages and differentiate into macrophage/dendritic cell lineages. A, WT-eGFP-HSCs grafted into Ctns−/− mice thyroid replace endogenous macrophages recruitment. Triple immunofluorescence for E-cadherin (white), F4/80 (red, common macrophage marker), and green fluorescent protein (GFP; green, HSCs) on thyroids of WT (a), Ctns−/− (b), and grafted Ctns−/− mice (c) is shown. a, In WT mice, macrophages are rare. b, In Ctns−/− mice, macrophages are abundant around and within follicles (red arrowheads and insert). c, In grafted Ctns−/− mice, much fewer endogenous F4/80+ macrophages (red arrowhead) are seen. Whereas some grafted HSCs also express the detectable F4/80 marker (yellow arrow), most do not (interstitial cluster around the asterisk). B, Phenotype of grafted HSCs. Multiplex immunofluorescence for laminin (white), GFP (green, HSCs), and specific markers of macrophages/dendritic cells: the common leukocyte marker (CD45); two common macrophages makers (F4/80 or CD11b); a dendritic cell and macrophage marker (MHCI); a monocyte and endothelial cell marker (Ly6C); and a macrophage and dendritic cell marker (CD11c). Most grafted HSCs are labeled for CD45 and some also express F4/80, CD11b, and MHCII markers (yellow arrow). In our conditions, Ly6C antibodies did not label HSCs but endothelium (#). HSCs that do not express a specific marker tested are indicated by white arrows. Endogenous inflammatory cells expressing CD45 and MHCII are indicated by a red arrowheads.
ment. Remarkably, although proinflammatory cytokines are known modifiers of thyroid epithelial barrier function (eg, reference 29), the inflammatory component of either cystinosis itself, or linked to HSC engraftment and infiltration, was apparently not sufficient to disrupt thyrocyte tight junction integrity, thus the epithelial barrier. Whether cytokines specify the tissue-specific cystinotic landscape and whether macrophage specification influences their ability to fully cross basement laminae deserve to be studied.

**Acknowledgments**

We gratefully acknowledge Dr Corinne Antignac (INSERM Unité 983, Paris, France) for providing the original Ctns−/−mice. We thank Dr A. Cominelli for comments as well as Y. Abid and T. Lac for their help with experiments.

Address all correspondence and requests for reprints to: Héloïse P. Gaide Chevronnay, PhD, de Duve Institute and Université Catholique de Louvain, 75 Avenue Hippocrate, PO Box B1.75.05, 1200 Brussels, Belgium. E-mail: heloise.gaidechevronnay@uclouvain.be; or Pierre J. Courtoy, MD, PhD, de Duve Institute and Université Catholique de Louvain, 75 Avenue Hippocrate, PO Box B1.75.05, 1200 Brussels, Belgium. E-mail: pierre.courtoy@uclouvain.be.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

H.G.C. is postdoctoral researcher, and C.E.P. is a research associate at Belgian Fonds de la Recherche Scientifique (Belgium).

This work was supported mainly by the Cystinosis Research Foundation, Belgian Science Policy Office-Interuniversity Attraction Poles Program Grant IAP P7/43-BeMGI, Belgian Fonds de la Recherche Scientifique and Actions de Recherche Concertées (to P.J.C. and C.E.P.), and National Institutes of Health Grants RO1-DK090058, RO1-DK099338, and R21-NS090066 (to S.C.). This work was also supported in part by Grant R37-DK15070 from the National Institutes of Health (to S.R.). The Platform for Imaging Cells supported in part by Grant R37-DK15070 from the National Institutes of Health Grants RO1-DK090058, RO1-DK099338, and R21-NS090066 (to S.C.). This work was also supported in part by Grant R37-DK15070 from the National Institutes of Health (to S.R.). The Platform for Imaging Cells supported in part by Grant R37-DK15070 from the National Institutes of Health.

Disclosure Summary: The authors have nothing to disclose.

**References**


The Endocrine Society. Downloaded from press.endocrine.org by [individualUser.displayName] on 20 June 2016 at 18:47 For personal use only. No other uses without permission. All rights reserved.